Damora Therapeutics, Inc. dismissed EY Godkendt Revisionspartnerselskab (EY Denmark) as its independent registered public accounting firm effective April 17, 2026. The company simultaneously engaged Ernst & Young LLP (EY US) as its new independent auditor effective April 17, 2026. The company reported no disagreements or reportable events with the outgoing auditor during the two most recent fiscal years and the subsequent interim period. The outgoing auditor, EY Denmark, confirmed its agreement with the company's disclosures regarding the dismissal.